Are cannabinoid drugs neurotoxic or neuroprotective?

Medical Hypotheses

Volumn 63, Issue 2, 2004, Pages 187-192

  Sarne, Y ^a   Keren, O ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; BAY 38 7271; CANNABINOID; CANNABINOID RECEPTOR AGONIST;

BRAIN INJURY; BRAIN PROTECTION; CELL CULTURE; CELL DEATH; CONCENTRATION RESPONSE; HUMAN; IN VIVO STUDY; LEARNING DISORDER; MEDICAL LITERATURE; MEMORY DISORDER; NERVE CELL; NERVE CELL LESION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALIA;

EID: 3242786506     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.02.043     Document Type: Article

References (71)

1. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74(2):1997;129-180
2. Howlett A.C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35:1995;607-634
3. Ameri A. The effects of cannabinoids on the brain. Prog. Neurobiol. 58(4):1999;315-348
4. Chaperon F., Thiebot M.H. Behavioral effects of cannabinoid agents in animals. Crit. Rev. Neurobiol. 13(3):1999;243-281
5. Mechoulam R., Panikashvili D., Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol. Med. 8(2):2002;58-61
6. Guzman M., Sanchez C., Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J. Mol. Med. 78(11):2001;613-625
7. Guzman M., Sanchez C., Galve-Roperh I. Cannabinoids and cell fate. Pharmacol. Ther. 95(2):2002;175-184
8. Guzman M. Neurons on cannabinoids: dead or alive? Br. J. Pharmacol. 140(3):2003;439-440
9. Baker D., Pryce G., Giovannoni G., Thompson A.J. The therapeutic potential of cannabis. Lancet Neurol. 2(5):2003;291-298
10. Bash R., Rubovitch V., Gafni M., Sarne Y. The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. Neurosignals. 12:2003;39-44
11. Rubovitch V., Gafni M., Sarne Y. The involvment of VEGF receptors and MAPK in the cannabinoid potentiation of calcium flux into N18TG2 neuroblastoma cells. Mol Brain Res. 120:2004;138-144
12. Rubovitch V., Gafni M., Sarne Y. The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Brain Res. Mol. Brain Res. 101(1-2):2002;93-102
13. Block R.I. Does heavy marijuana use impair human cognition and brain function? JAMA. 275(7):1996;560-561
14. Ehrenreich H., Rinn T., Kunert H.J., et al. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl). 142(3):1999;295-301
15. Pope H.G. Jr., Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA. 275(7):1996;521-527
16. Schwartz R.H. Heavy marijuana use and recent memory impairment. Psychiatr. Annals. 21:1991;80-82
17. Solowij N., Michie P.T., Fox A.M. Differential impairments of selective attention due to frequency and duration of cannabis use. Biol. Psychiatr. 37(10):1995;731-739
18. Mouzak A., Agathos P., Kerezoudi E., Mantas A., Vourdeli-Yiannakoura E. Transient ischemic attack in heavy cannabis smokers - how 'safe' is it? Eur. Neurol. 44(1):2000;42-44
19. Herning R.I., Better W.E., Tate K., Cadet J.L. Marijuana abusers are at increased risk for stroke. Preliminary evidence from cerebrovascular perfusion data. Ann. NY Acad. Sci. 939:2001;413-415
20. Zachariah S.B. Stroke after heavy marijuana smoking. Stroke. 22(3):1991;406-409
21. Stiglick A., Llewellyn M.E., Kalant H. Residual effects of prolonged cannabis treatment on shuttle-box avoidance in the rat. Psychopharmacology (Berl). 84(4):1984;476-479
22. Stiglick A., Kalant H. Residual effects of prolonged cannabis administration on exploration and DRL performance in rats. Psychopharmacology (Berl). 77(2):1982;124-128
23. Fehr K.A., Kalant H., Leblanc A.E. Residual learning deficit after heavy exposure to cannabis or alcohol in rats. Science. 192(4245):1976;1249-1251
24. Morris R.G., Garrud P., Rawlins J.N., O'keefe J. Place navigation impaired in rats with hippocampal lesions. Nature. 297(5868):1982;681-683
25. Lawston J., Borella A., Robinson J.K., Whitaker-Azmitia P.M. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-222. Brain Res. 877(2):2000;407-410
26. Scallet A.C. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol. Biochem. Behav. 40(3):1991;671-676
27. Scallet A.C., Uemura E., Andrews A., et al. Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res. 436(1):1987;193-198
28. Landfield P.W., Cadwallader L.B., Vinsant S. Quantitative changes in hippocampal structure following long-term exposure to delta 9- tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain Res. 443(1-2):1988;47-62
29. Chan G.C., Hinds T.R., Impey S., Storm D.R. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J. Neurosci. 18(14):1998;5322-5332
30. Nagayama T., Sinor A.D., Simon R.P., et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19(8):1999;2987-2995
31. Van Der Stelt M., Veldhuis W.B., Bar P.R., et al. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J. Neurosci. 21(17):2001;6475-6479
32. Van Der Stelt M., Veldhuis W.B., Van Haaften G.W., et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21(22):2001;8765-8771
33. Panikashvili D., Simeonidou C., Ben-Shabat S., et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 413(6855):2001;527-531
34. Mauler F., Hinz V., Augstein K.H., Fassbender M., Horvath E. Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Res. 989(1):2003;99-111
35. Marsicano G., Goodenough S., Monory K., et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 302(5642):2003;84-88
36. Shen M., Thayer S.A. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54(3):1998;459-462
37. Abood M.E., Rizvi G., Sallapudi N., Mcallister S.D. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. 309(3):2001;197-201
38. Hampson A.J., Grimaldi M. Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur. J. Neurosci. 13(8):2001;1529-1536
39. Hampson A.J., Grimaldi M., Axelrod J., Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA. 95(14):1998;8268-8273
40. Marsicano G., Moosmann B., Hermann H., Lutz B., Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. 80(3):2002;448-456
41. Davis W.M., Moreton J.E., King W.T., Pace H.B. Marihuana on locomotor activity: biphasic effect and tolerance development. Res. Commun. Chem. Pathol. Pharmacol. 3(1):1972;29-35
42. Sulcova E., Mechoulam R., Fride E. Biphasic effects of anandamide. Pharmacol. Biochem. Behav. 59(2):1998;347-352
43. Taylor D.A., Fennessy M.R. Biphasic nature of the effects of delta9-tetrahydrocannabinol on body temperature and brain amines of the rat. Eur. J. Pharmacol. 46(2):1977;93-99
44. Glass M., Felder C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17(14):1997;5327-5333
45. Maneuf Y.P., Brotchie J.M. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br. J. Pharmacol. 120(8):1997;1397-1398
46. 2+ transient in NG108-15 cells. J. Biochem. (Tokyo). 122(4):1997;890-895
47. Acquas E., Pisanu A., Marrocu P., Goldberg S.R., Di Chiara G. Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study. Eur. J. Pharmacol. 419(2-3):2001;155-161
48. Acquas E., Pisanu A., Marrocu P., Di Chiara G. Cannabinoid CB (1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo. Eur. J. Pharmacol. 401(2):2000;179-185
49. Tzavara E.T., Wade M., Nomikos G.G. Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J. Neurosci. 23(28):2003;9374-9384
50. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. 81(3):1999;163-221
51. Caulfield M.P., Brown D.A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106(2):1992;231-232
52. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA. 89(9):1992;3825-3829
53. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 78(1):1997;43-50
54. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16(14):1996;4322-4334
55. Hillard C.J., Muthian S., Kearn C.S. Effects of CB (1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett. 459(2):1999;277-281
56. Facchinetti F., Del Giudice E., Furegato S., Passarotto M., Leon A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia. 41(2):2003;161-168
57. Maccarrone M., Lorenzon T., Bari M., Melino G., Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275(41):2000;31938-31945
58. Galve-Roperh I., Rueda D., Gomez Del Pulgar T., Velasco G., Guzman M. Mechanism of extracellular signal-regulated kinase activation by the CB (1) cannabinoid receptor. Mol. Pharmacol. 62(6):2002;1385-1392
59. Galve-Roperh I., Sanchez C., Cortes M.L., et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6(3):2000;313-319
60. Rueda D., Galve-Roperh I., Haro A., Guzman M. The CB (1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol. Pharmacol. 58(4):2000;814-820
61. Derkinderen P., Ledent C., Parmentier M., Girault J.A. Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J. Neurochem. 77(3):2001;957-960
62. Bouaboula M., Poinot-Chazel C., Bourrie B., et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312(Pt 2):1995;637-641
63. Downer E.J., Fogarty M.P., Campbell V.A. Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons. Br. J. Pharmacol. 140(3):2003;547-557
64. Basu S., Kolesnick R. Stress signals for apoptosis: ceramide and c-Jun kinase. Oncogene. 17(25):1998;3277-3285
65. Agell N., Bachs O., Rocamora N., Villalonga P. Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell Signal. 14(8):2002;649-654
66. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270(5240):1995;1326-1331
67. Rubovitch V. Stimulatory effects of cannabinoid and opioid drugs. Ph.D. Thesis. Tel-Aviv University;2003
68. Solowij N., Stephens R.S., Roffman R.A., et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. 287(9):2002;1123-1131
69. Agurell S., Halldin M., Lindgren J.E., et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev. 38(1):1986;21-43
70. Feigenbaum J.J., Bergmann F., Richmond S.A., et al. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl. Acad. Sci. USA. 86(23):1989;9584-9597
71. Gallily R., Breuer A., Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur. J. Pharmacol. 406(1):2000;R5-R7